Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 8/20 | 0.33 |
| ▸ | LDHB | P07195 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657669 | 0.83 | LMNA (0.39) | TSHRLMNAHAO1LDHALDHB | |
| SCHEMBL1856547 | 0.79 | CA12 (0.37) | TSHRLMNAHAO1POLB | |
| SCHEMBL11292131 | 0.78 | CA12 (0.39) | TSHRLMNA | |
| SCHEMBL83809 | 0.75 | CYP1A2 (0.50) | HAO1MEN1KMT2A | |
| SCHEMBL23732134 | 0.73 | LMNA (0.35) | TSHRLMNAHAO1LDHALDHB | |
| SCHEMBL21340222 | 0.73 | LMNA (0.35) | TSHRLMNAHAO1LDHALDHB | |
| SCHEMBL5636183 | 0.73 | SLC6A2 (0.41) | TSHRLMNAMEN1KMT2ATP53 | |
| SCHEMBL5636187 | 0.73 | SLC6A2 (0.41) | TSHRLMNAMEN1KMT2ATP53 | |
| Hydrochloric Acid SCHEMBL72071 | 0.73 | CYP1A2 (0.49) | MEN1KMT2A | |
| SCHEMBL4869816 | 0.70 | SLC6A2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | disclosed |
| EP-2440521-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-7893099-B2 | Cyclopentane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-02-22 | — | — | US | disclosed |
| WO-2010142650-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | TBXA2R, ADORA1, CNR1 | DPP4 3574/4885TSHR 2108/4885LMNA 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.